Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[rkp72]

No. This 295 patent is the manufacturing or synthesizing patent. Nice to have but not nearly as important as the "use" patent, which, if and when granted, will provide STSI exclusive rights for the use of certain isonomers of anatabine citrate on specific medical conditions. If peer-reviewed studies prove that these isonomers are highly effective against the said conditions, the granting of the "use" patent will provide the impetus to the stock price that the longs are looking for. Main problem is we don't know if and when STSI will get this and how STSI will survive cash-wise before it does.